Inovio Pharmaceuticals, Inc. (INO)
| Market Cap | 106.52M +53.7% |
| Revenue (ttm) | n/a -70.0% |
| Net Income | -84.93M |
| EPS | -1.56 |
| Shares Out | 81.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,950,912 |
| Open | 1.350 |
| Previous Close | 1.360 |
| Day's Range | 1.300 - 1.410 |
| 52-Week Range | 1.030 - 2.979 |
| Beta | 1.44 |
| Analysts | Buy |
| Price Target | 4.50 (+419.23%) |
| Earnings Date | May 13, 2026 |
About INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and i... [Read more]
Financial Performance
In 2025, Inovio Pharmaceuticals's revenue was $65,343, a decrease of -69.99% compared to the previous year's $217,756. Losses were -$84.95 million, -20.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for INO stock is "Buy." The 12-month stock price target is $4.5, which is an increase of 419.23% from the latest price.
News
Inovio Pharmaceuticals Earnings Call Transcript: Q1 2026
INO-3107 advanced toward FDA approval with no new issues in mid-cycle review; cash runway extended into Q1 2027 after a $16M equity raise. Commercial plans leverage competitor insights, and pipeline progress continues via partnerships and dPROT technology.
INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee ...
Inovio options imply 15.1% move in share price post-earnings
Pre-earnings options volume in Inovio (INO) is normal with calls leading puts 72:1. Implied volatility suggests the market is anticipating a move near 15.1%, or 21c, after results are released.
Options Volatility and Implied Earnings Moves Today, May 13, 2026
Today, several major companies are expected to report earnings: Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Microvision (MVIS), Toyota Motor (TM), Wix (WIX), Alibaba (BABA), Eos Energy Enterpr...
Hantavirus cases spark surge in pharma and biotech stocks — here's why
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
INOVIO to Participate in Upcoming Scientific Conferences
PLYMOUTH MEETING, Pa., May 8, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-relate...
INOVIO to Report First Quarter Financial Results on May 13, 2026
PLYMOUTH MEETING, Pa., May 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-relate...
INOVIO Announces Pricing of $17.5 Million Public Offering
PLYMOUTH MEETING, Pa., April 2, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prote...
INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prote...
INOVIO to Participate in Upcoming Scientific Conference
PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...
Shareholders Sue Inovio Pharmaceuticals Over DNA Technology Claims
A class action lawsuit was filed against Inovio Pharmaceuticals ($INO) on February 6, 2026. Plaintiffs – shareholders – in the federal securities class action allege that they acquired Inovio stock…
Inovio Pharmaceuticals Earnings Call Transcript: Q4 2025
BLA for INO-3107 accepted by FDA with a PDUFA date of October 30, 2026, though eligibility for Accelerated Approval is under review. Cash runway extends into Q4 2026, with commercial launch preparations and pipeline partnerships advancing.
INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U...
Options Volatility and Implied Earnings Moves Today, March 12, 2026
Today, several major companies are expected to report earnings: Adobe (ADBE), Ballard Power Systems (BLDP), Dollar General (DG), Inovio Pharmaceuticals (INO), Lennar (LEN), Wheaton Precious Metals (WP...
Inovio Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026
INO-3107, a DNA medicine for RRP, is under FDA review with a PDUFA date in October and shows strong efficacy in reducing surgeries. Differentiation from competitors includes in-office administration and no need for surgeries during treatment. Commercial and regulatory preparations are well advanced.
INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
PLYMOUTH MEETING, Pa., March 5, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-asso...
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of b...
Inovio, Akeso announce clinical collaboration
Inovio (INO) and Akeso announced that they have entered into a clinical trial collaboration and supply agreement to evaluate INO-5412, Inovio’s DNA immunotherapy candidate, in combination with cadonil...
INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
Collaboration will evaluate INOVIO's INO-5412 (INO-5401 plus INO-9012) in combination with Akeso's cadonilimab as a potential treatment for glioblastoma (GBM), the most common and aggressive form of b...
Inovio Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The discussion highlighted progress toward FDA approval for INO-3107, a DNA-based therapy for RRP, with strong clinical data showing reduced surgeries and a favorable safety profile. The company is focused on regulatory milestones, market opportunity, and advancing its pipeline through partnerships.
INOVIO to Participate in Upcoming Scientific and Investor Conferences
PLYMOUTH MEETING, Pa., Feb. 12, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-asso...
Inovio announces U.S. FDA accepted BLA for INO-3107
INOVIO (INO) announced that the U.S. Food and Drug Administration, FDA, accepted the company’s Biologics License Application, BLA, for INO-3107 for review as a potential treatment for adults with RRP.
FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
PLYMOUTH MEETING, Pa. , Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-re...
INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa. , Dec. 19, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-re...
Inovio Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
INO-3107 demonstrated significant reduction in surgeries for RRP, with a strong safety profile and patient preference over competitors. The company is preparing for a potential mid-next-year FDA decision, expanding its pipeline, and advancing in vivo protein production technology.